Newsroom

Sorted by: Latest
-

Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

TOKYO--(BUSINESS WIRE)--Enhertu Showed Statistically Significant & Clinically Meaningful PFS Improvement as First-Line Treatment of Patients with HER2 Mutant Advanced NSCLC...
-

Pershing Square Holdings, Ltd. UK Regulatory Announcement: Transaction in Own Shares

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 14 August 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 14 August 2026 Number of Public Shares Purchased: 29,4...
-

Valerio Therapeutics et Etherna Immunotherapies progressent vers la finalisation de la documentation relative à l’Acquisition envisagée

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), société de biotechnologie au stade clinique, pionnière dans le domaine des thérapies de précision de nouvelle génération («Valerio» ou la « Société »), fait un point sur le projet d’acquisition de 100% du capital social d’Etherna Immunotherapies NV (« Etherna ») (l’« Acquisition »). Le 1er juillet 2026, Valerio a annoncé avoir soumis une offre ferme en vue de l’Acquisition sur la base d’une valeur...
-

Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), provides an update on the contemplated acquisition of 100% of the share capital of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). On July 1, 2026, Valerio announced the submission of a binding offer for the Acquisition on the basis of an enterprise value of EUR 30 million....
-

First Trust Portfolios UK Regulatory Announcement: First Trust Global Portfolios Management Limited Announces Distribution for Certain Sub-Funds of First Trust Global Funds ICAV

LONDON--(BUSINESS WIRE)--  First Trust Global Portfolios Management Limited (“FTGPM”) announces the declaration of the monthly distribution for First Trust Vest S&P 500® Dividend Aristocrats Target Income UCITS ETF (the “Fund”). ISIN Fund Name Frequency Dividend per Share IE000SNMGYT5 First Trust Vest S&P 500® Dividend Aristocrats Target Income UCITS ETF Class B Monthly $0.1493 (USD) The Fund’s investment manager is First Trust Advisors L.P. (“FTA”). FTA has appointed Vest Financial LLC...
-

T-Mobile Expands Network Recovery and Customer Support Across Hawaiʻi Following Hurricane Lala

BELLEVUE, Wash.--(BUSINESS WIRE)--As Lala moves west across Hawaiʻi, T‑Mobile (NASDAQ: TMUS) teams are expanding response and recovery efforts across the islands, restoring connectivity, supporting customers and working alongside emergency officials as communities begin to recover. Restoring Connectivity Across Hawaiʻi Network impacts have shifted as Lala has continued west, driven overwhelmingly by widespread commercial power outages. Crews are in the field across multiple islands restoring af...
-

Pied Piper Launches New Era of Continuous Retailer Performance Monitoring and Proactive Alerts

AUSTIN, Texas--(BUSINESS WIRE)--New Pied Piper subscription programs identify customer-handling problems as they occur, and proactively alert local management when action is needed....
-

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)--EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law...
-

ONT Investors Have Opportunity to Join Onterris, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)--ONT Investors Have Opportunity to Join Onterris, Inc. Fraud Investigation with SBS Law...
-

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)--TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law...